These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25703419)

  • 161. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 162. Updates and current recommendations for the management of patients with non-ST-elevation acute coronary syndromes: what it means for clinical practice.
    Cayla G; Silvain J; Collet JP; Montalescot G
    Am J Cardiol; 2015 Mar; 115(5 Suppl):10A-22A. PubMed ID: 25728969
    [TBL] [Abstract][Full Text] [Related]  

  • 163. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
    Lhermusier T; Lipinski MJ; Tantry US; Escarcega RO; Baker N; Bliden KP; Magalhaes MA; Ota H; Tian W; Pendyala L; Minha S; Chen F; Torguson R; Gurbel PA; Waksman R
    Am J Cardiol; 2015 Mar; 115(6):716-23. PubMed ID: 25728845
    [TBL] [Abstract][Full Text] [Related]  

  • 164. Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy.
    Quatromoni N; Tuteja S; Kolanksy DM; Matthai WH; Giri J
    Curr Atheroscler Rep; 2015 May; 17(5):501. PubMed ID: 25732742
    [TBL] [Abstract][Full Text] [Related]  

  • 165. Structural and functional characterization of a specific antidote for ticagrelor.
    Buchanan A; Newton P; Pehrsson S; Inghardt T; Antonsson T; Svensson P; Sjögren T; Öster L; Janefeldt A; Sandinge AS; Keyes F; Austin M; Spooner J; Gennemark P; Penney M; Howells G; Vaughan T; Nylander S
    Blood; 2015 May; 125(22):3484-90. PubMed ID: 25788700
    [TBL] [Abstract][Full Text] [Related]  

  • 166. New oral anticoagulants and perioperative management of anticoagulant/antiplatelet agents.
    Rahman A; Latona J
    Aust Fam Physician; 2014 Dec; 43(12):861-6. PubMed ID: 25705736
    [TBL] [Abstract][Full Text] [Related]  

  • 167. Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Jia M; Li Z; Chu H; Li L; Chen K
    Med Sci Monit; 2015 Apr; 21():1131-7. PubMed ID: 25893318
    [TBL] [Abstract][Full Text] [Related]  

  • 168. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials.
    Zaccardi F; Pitocco D; Willeit P; Laukkanen JA
    Atherosclerosis; 2015 Jun; 240(2):439-45. PubMed ID: 25897998
    [TBL] [Abstract][Full Text] [Related]  

  • 169. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 170. Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes.
    Husted S; Boersma E
    Am J Ther; 2016; 23(6):e1876-e1889. PubMed ID: 25830867
    [TBL] [Abstract][Full Text] [Related]  

  • 171. Prognostic impact of clopidogrel pretreatment in patients with acute coronary syndrome managed invasively.
    Almendro-Delia M; Gonzalez-Torres L; Garcia-Alcantara Á; Reina-Toral A; Arboleda Sánchez JA; Rodríguez Yañez JC; Hidalgo-Urbano R; García Rubira JC;
    Am J Cardiol; 2015 Apr; 115(8):1019-26. PubMed ID: 25728644
    [TBL] [Abstract][Full Text] [Related]  

  • 172. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis.
    Lemesle G; Schurtz G; Bauters C; Hamon M
    J Thromb Haemost; 2015 Jun; 13(6):931-42. PubMed ID: 25809392
    [TBL] [Abstract][Full Text] [Related]  

  • 173. Long-term use of ticagrelor in patients with prior myocardial infarction.
    Bonaca MP; Bhatt DL; Cohen M; Steg PG; Storey RF; Jensen EC; Magnani G; Bansilal S; Fish MP; Im K; Bengtsson O; Oude Ophuis T; Budaj A; Theroux P; Ruda M; Hamm C; Goto S; Spinar J; Nicolau JC; Kiss RG; Murphy SA; Wiviott SD; Held P; Braunwald E; Sabatine MS;
    N Engl J Med; 2015 May; 372(19):1791-800. PubMed ID: 25773268
    [TBL] [Abstract][Full Text] [Related]  

  • 174. Randomized, Double-Blind, Dose-Finding, Phase II Study of Prasugrel in Japanese Patients Undergoing Elective Percutaneous Coronary Intervention.
    Kimura T; Isshiki T; Ogawa H; Yokoi H; Yamaguchi T; Ikeda Y
    J Atheroscler Thromb; 2015; 22(6):557-69. PubMed ID: 25737192
    [TBL] [Abstract][Full Text] [Related]  

  • 175. Differential effects of platelets and platelet inhibition by ticagrelor on TLR2- and TLR4-mediated inflammatory responses.
    Tunjungputri RN; van der Ven AJ; Riksen N; Rongen G; Tacke S; van den Berg TN; Fijnheer R; Gomes ME; Dinarello CA; van de Veerdonk FL; Gasem MH; Netea MG; Joosten LA; de Groot PG; de Mast Q
    Thromb Haemost; 2015 May; 113(5):1035-45. PubMed ID: 25716539
    [TBL] [Abstract][Full Text] [Related]  

  • 176. Antiplatelet therapy. Long-term ticagrelor use in patients with history of MI.
    Mearns BM
    Nat Rev Cardiol; 2015 May; 12(5):260. PubMed ID: 25824506
    [No Abstract]   [Full Text] [Related]  

  • 177. One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction.
    Lattuca B; Fabbro-Peray P; Leclercq F; Schmutz L; Ledermann B; Cornillet L; Benezet JF; Macia JC; de La Coussaye JE; Messner-Pellenc P; Cayla G
    Arch Cardiovasc Dis; 2016 May; 109(5):337-47. PubMed ID: 27079469
    [TBL] [Abstract][Full Text] [Related]  

  • 178. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial.
    Valgimigli M; Gagnor A; Calabró P; Frigoli E; Leonardi S; Zaro T; Rubartelli P; Briguori C; Andò G; Repetto A; Limbruno U; Cortese B; Sganzerla P; Lupi A; Galli M; Colangelo S; Ierna S; Ausiello A; Presbitero P; Sardella G; Varbella F; Esposito G; Santarelli A; Tresoldi S; Nazzaro M; Zingarelli A; de Cesare N; Rigattieri S; Tosi P; Palmieri C; Brugaletta S; Rao SV; Heg D; Rothenbühler M; Vranckx P; Jüni P;
    Lancet; 2015 Jun; 385(9986):2465-76. PubMed ID: 25791214
    [TBL] [Abstract][Full Text] [Related]  

  • 179. Dual antiplatelet therapy for coronary artery disease.
    Lee CW
    Circ J; 2015; 79(2):255-62. PubMed ID: 25744739
    [TBL] [Abstract][Full Text] [Related]  

  • 180. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
    Wiviott SD; Steg PG
    Lancet; 2015 Jul; 386(9990):292-302. PubMed ID: 25777663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.